PL4039675T3 - Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe - Google Patents
Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenyloweInfo
- Publication number
- PL4039675T3 PL4039675T3 PL21211015.9T PL21211015T PL4039675T3 PL 4039675 T3 PL4039675 T3 PL 4039675T3 PL 21211015 T PL21211015 T PL 21211015T PL 4039675 T3 PL4039675 T3 PL 4039675T3
- Authority
- PL
- Poland
- Prior art keywords
- phenyl
- hydroxyacetylamine
- methyl
- compounds
- phenyl compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207 | 2017-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4039675T3 true PL4039675T3 (pl) | 2025-01-07 |
Family
ID=58606227
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18718570T PL3612519T3 (pl) | 2017-04-18 | 2018-04-11 | Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe |
| PL21211015.9T PL4039675T3 (pl) | 2017-04-18 | 2018-04-11 | Związki fenylo-2-hydroksyacetyloamino-2-metylo-fenylowe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18718570T PL3612519T3 (pl) | 2017-04-18 | 2018-04-11 | Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11655214B2 (pl) |
| EP (2) | EP3612519B1 (pl) |
| JP (2) | JP7110232B2 (pl) |
| KR (2) | KR102575246B1 (pl) |
| CN (2) | CN117510405A (pl) |
| AU (2) | AU2018255191B2 (pl) |
| BR (1) | BR112019021867A2 (pl) |
| CO (1) | CO2019012767A2 (pl) |
| CR (1) | CR20190519A (pl) |
| CY (1) | CY1125150T1 (pl) |
| DK (2) | DK3612519T3 (pl) |
| ES (2) | ES2906847T3 (pl) |
| FI (1) | FI4039675T3 (pl) |
| HR (2) | HRP20241188T1 (pl) |
| HU (2) | HUE068023T2 (pl) |
| IL (2) | IL270005B (pl) |
| LT (2) | LT3612519T (pl) |
| MX (2) | MX389724B (pl) |
| MY (1) | MY199442A (pl) |
| PH (1) | PH12019502363B1 (pl) |
| PL (2) | PL3612519T3 (pl) |
| PT (2) | PT3612519T (pl) |
| RS (2) | RS65914B1 (pl) |
| SA (1) | SA519410320B1 (pl) |
| SG (1) | SG11201909680UA (pl) |
| SI (2) | SI3612519T1 (pl) |
| SM (2) | SMT202400357T1 (pl) |
| WO (1) | WO2018194885A1 (pl) |
| ZA (1) | ZA201906811B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3612519T1 (sl) * | 2017-04-18 | 2022-04-29 | Eli Lilly And Company | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine |
| KR102897382B1 (ko) | 2018-03-26 | 2025-12-08 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 미세 잔존 암을 치료하는 방법 |
| WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| KR20220066290A (ko) * | 2019-08-29 | 2022-05-24 | 히버셀, 인크. | Perk 억제 피롤로피리미딘 화합물 |
| PH12022551081A1 (en) | 2019-11-06 | 2024-06-19 | Remedy Plan Inc | Cancer treatments targeting cancer stem cells |
| WO2021231788A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds to treat viral infections |
| WO2021231782A1 (en) * | 2020-05-13 | 2021-11-18 | Hibercell, Inc. | Perk inhibitors for treating viral infections |
| CN113234029B (zh) * | 2021-05-25 | 2022-03-22 | 白银康寓信生物科技有限公司 | 一种2-氨基-3,5-二卤代吡嗪的合成方法 |
| JP2026513203A (ja) * | 2023-03-30 | 2026-04-23 | ハイバーセル，インコーポレイテッド | （ｒ）－２－アミノ－５－（４－（２－（３，５－ジフルオロフェニル）－２－ヒドロキシアセトアミド）－２－メチルフェニル）－ｎ－イソプロピルニコチンアミドの結晶形態及びその使用方法 |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| WO2005030933A2 (en) | 2003-09-24 | 2005-04-07 | Genera Doo | Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| CN101253152A (zh) * | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| WO2010080992A1 (en) | 2009-01-09 | 2010-07-15 | The Trustees Of The University Of Pennsylvania | Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| KR20150044952A (ko) * | 2012-08-23 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드 |
| WO2014170706A1 (en) | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3067356B1 (en) | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| JP2017507967A (ja) | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｐｅｒｋ阻害剤として作用する化合物 |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| EP3218378B1 (en) | 2014-11-14 | 2020-01-08 | Nerviano Medical Sciences S.r.l. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| BR112018001190A2 (pt) * | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| EP3481831B1 (en) | 2016-07-07 | 2023-09-06 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| CN106748989B (zh) | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| SI3612519T1 (sl) | 2017-04-18 | 2022-04-29 | Eli Lilly And Company | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3492454A1 (en) | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| KR102897382B1 (ko) | 2018-03-26 | 2025-12-08 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 미세 잔존 암을 치료하는 방법 |
| AU2019297428C1 (en) | 2018-07-06 | 2023-03-23 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
-
2018
- 2018-04-11 SI SI201830572T patent/SI3612519T1/sl unknown
- 2018-04-11 SM SM20240357T patent/SMT202400357T1/it unknown
- 2018-04-11 SG SG11201909680U patent/SG11201909680UA/en unknown
- 2018-04-11 RS RS20240950A patent/RS65914B1/sr unknown
- 2018-04-11 HR HRP20241188TT patent/HRP20241188T1/hr unknown
- 2018-04-11 CR CR20190519A patent/CR20190519A/es unknown
- 2018-04-11 EP EP18718570.7A patent/EP3612519B1/en active Active
- 2018-04-11 PH PH1/2019/502363A patent/PH12019502363B1/en unknown
- 2018-04-11 HU HUE21211015A patent/HUE068023T2/hu unknown
- 2018-04-11 LT LTEPPCT/US2018/027005T patent/LT3612519T/lt unknown
- 2018-04-11 FI FIEP21211015.9T patent/FI4039675T3/fi active
- 2018-04-11 BR BR112019021867-0A patent/BR112019021867A2/pt not_active Application Discontinuation
- 2018-04-11 DK DK18718570.7T patent/DK3612519T3/da active
- 2018-04-11 LT LTEP21211015.9T patent/LT4039675T/lt unknown
- 2018-04-11 PL PL18718570T patent/PL3612519T3/pl unknown
- 2018-04-11 HR HRP20220263TT patent/HRP20220263T1/hr unknown
- 2018-04-11 SI SI201831149T patent/SI4039675T1/sl unknown
- 2018-04-11 HU HUE18718570A patent/HUE057745T2/hu unknown
- 2018-04-11 EP EP21211015.9A patent/EP4039675B1/en active Active
- 2018-04-11 RS RS20220154A patent/RS62933B1/sr unknown
- 2018-04-11 ES ES18718570T patent/ES2906847T3/es active Active
- 2018-04-11 WO PCT/US2018/027005 patent/WO2018194885A1/en not_active Ceased
- 2018-04-11 CN CN202310753648.5A patent/CN117510405A/zh active Pending
- 2018-04-11 KR KR1020197033523A patent/KR102575246B1/ko active Active
- 2018-04-11 ES ES21211015T patent/ES2988739T3/es active Active
- 2018-04-11 MY MYPI2019006116A patent/MY199442A/en unknown
- 2018-04-11 MX MX2019012428A patent/MX389724B/es unknown
- 2018-04-11 PL PL21211015.9T patent/PL4039675T3/pl unknown
- 2018-04-11 CN CN201880033126.5A patent/CN110831927B/zh active Active
- 2018-04-11 SM SM20220100T patent/SMT202200100T1/it unknown
- 2018-04-11 JP JP2019556703A patent/JP7110232B2/ja active Active
- 2018-04-11 US US16/606,410 patent/US11655214B2/en active Active
- 2018-04-11 AU AU2018255191A patent/AU2018255191B2/en active Active
- 2018-04-11 PT PT187185707T patent/PT3612519T/pt unknown
- 2018-04-11 PT PT212110159T patent/PT4039675T/pt unknown
- 2018-04-11 KR KR1020237029674A patent/KR20230129627A/ko not_active Ceased
- 2018-04-11 DK DK21211015.9T patent/DK4039675T3/da active
-
2019
- 2019-10-16 ZA ZA2019/06811A patent/ZA201906811B/en unknown
- 2019-10-17 SA SA519410320A patent/SA519410320B1/ar unknown
- 2019-10-17 MX MX2022001310A patent/MX2022001310A/es unknown
- 2019-10-17 IL IL270005A patent/IL270005B/en unknown
- 2019-11-15 CO CONC2019/0012767A patent/CO2019012767A2/es unknown
-
2021
- 2021-12-09 IL IL288822A patent/IL288822B2/en unknown
-
2022
- 2022-03-01 CY CY20221100173T patent/CY1125150T1/el unknown
- 2022-07-18 AU AU2022206702A patent/AU2022206702B2/en active Active
- 2022-07-20 JP JP2022115300A patent/JP7331212B2/ja active Active
-
2023
- 2023-04-13 US US18/300,237 patent/US12590064B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| EP3578560A4 (en) | QUINAZOLINE COMPOUND | |
| CL2018000524S1 (es) | Golilla | |
| EP3589248A4 (en) | CRYOTHERAPIES | |
| EP3609871A4 (en) | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| EP3588580A4 (en) | SCHOTTKY MOS TRENCH DIODE | |
| DK4039675T3 (da) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| MA49750A (fr) | Dihydrooxadiazinones | |
| EP3721165C0 (en) | MILITARY CHARGE | |
| DK3568655T3 (da) | Rekuperator | |
| DK3571580T3 (da) | Load-logical-and-shift-guarded-instruktion | |
| LT3464336T (lt) | Junginiai | |
| DK3612237T3 (da) | Genterapi | |
| EP3611402A4 (en) | SERVO CYLINDER | |
| EP3615471A4 (en) | PLASMA PHOTOELECTRONIC IMMUNE SENSOR | |
| DK3576686T3 (da) | Brokbind | |
| DK3568506T3 (da) | Offeranode | |
| DK3672941T3 (da) | Pyridylpyridonforbindelser | |
| HUE056928T2 (hu) | Új vegyületek | |
| DK3672962T3 (da) | Morpholinylpyridonforbindelser | |
| DK3510051T3 (da) | Carboxylalkylchitosan | |
| DK3676276T3 (da) | Spirothietannukleosider | |
| DK3395159T3 (da) | Ballepresse |